A phase IV study to evaluate decreased dose frequency in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA) who experience laboratory abnormalities during treatment with tocilizumab

Efficacy: � To explore the efficacy of TCZ in reduced dosing frequency regimens (Q3W and Q4W, as appropriate) using Juvenile Arthritis Disease Activity Score (JADAS)-71, JIA flare, and fever Pharmacodynamic: � To describe the pharmacodynamics, using sIL-6R and C-reactive protein (CRP), and immunogenicity of TCZ in reduced dosing frequency regimens.